Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse

References

• Arlin Z. Current status of amsacrine combination chemotherapy programs in acute leukaemia. Cancer Treatment Reports 1983; 67: 967–970
   PubMedGoogle Scholar
• Baguley B. C., Denny W. A., Atwell G. J., Finlay G. J., Rewcastle G. W., Twigden S. J., Wilson W. R. Synthesis, antitumour activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridine carboxamide. Cancer Research 1984; 44: 3245–3251
   PubMed Web of Science ®Google Scholar
• Becker B. A., Plaa G. A. Assessment of liver function in mice. Laboratory and Animal Care 1967; 17: 267–272
   PubMedGoogle Scholar
• Cain B. F., Atwell G. J. The experimental antitumour properties of three congeners of the acridinylmethanesulphonanilide (AMSA) series. European Journal of Cancer 1974; 10: 539–549
   PubMed Web of Science ®Google Scholar
• Cysyk R. L., Shoemaker D. D., Adamson R. H. The pharmacological disposition of 4′-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. Drug Metabolism and Disposition 1977; 5: 579–590
   PubMed Web of Science ®Google Scholar
• Denny W. A., Cain B. F., Atwell G. J., Hansch C., Panthananickal A., Leo A. Potential antitumor agents. 36. Quantitative relationships between experimental antitumour activity, toxicity, and structure for the general class of 9-anilinoacridine antitumour agents. Journal of Medicinal Chemistry 1982; 25: 276–315
   PubMed Web of Science ®Google Scholar
• Denny W. A., Atwell G. J., Baguley B. C. Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine. Journal of Medicinal Chemistry 1984; 27: 363–367
   PubMed Web of Science ®Google Scholar
• Denny W. A., Atwell G. J., Rewcastle G. W., Baguley B. C. Potential antitumor agents. 49. 5-Substituted derivatives of N-[2-dimethylamino)-ethyl]-9-aminoacridine-4-carboxamide with in vivo solid tumour activity. Journal of Medicinal Chemistry 1987; 30: 658–663
   PubMed Web of Science ®Google Scholar
• Gaudich K., Przybylski M. Field desorption mass spectrometric characterization of thiol conjugates related to the oxidative metabolism of 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Biomedical Mass Spectrometry 1983; 10: 292–299
   PubMedGoogle Scholar
• Jurlina J. L., Lindsay A., Packer J. E., Baguley B. C., Denny W. A. Redox chemistry of the 9-anilinoacridine class of antitumor agents. Journal of Medicinal Chemistry 1987; 30: 473–480
   PubMed Web of Science ®Google Scholar
• Kestell P., Paxton J. W., Robertson I. G. C., Evans P. C., Dormer R. A., Baguley B. C. Thiolytic cleavage and binding of the antitumour agent CI-921 in blood. Drug Metabolism and Drug Interactions 1988; 6: 327–335
   PubMedGoogle Scholar
• Kestell P., Paxton J. W., Evans P. C., Young D., Jurlina J. L., Robertson I. G. C., Baguley B. C. Disposition of amsacrine and its analogue 9-(2-methoxy-4[(methyl-sulfonyl)amino]phenyl)amino)-N,5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver and Lewis lung tumors in mice. Cancer Research 1990; 50: 503–508
   PubMed Web of Science ®Google Scholar
• Krishnamurthy V. V., Casida J. E., Dohn D. R. Complete spectral assignments of the pesticide metabolite S-(2,3-dihydroxy-1-propyl)glutathione. Magnetic Resonance in Chemistry 1988; 26: 542–546
   Web of Science ®Google Scholar
• Lee H. H., Palmer B. D., Denny W. A. Reactivity to nucleophiles of quinoneimine and quinonediimine metabolites of the antitumour drug amsacrine and related compounds. Journal of Organic Chemistry 1988; 53: 6042–6047
   Google Scholar
• Przybylski M., Cyrsyk R. L., Shoemaker D., Adamson R. H. Identification of conjugation and cleavage products in the thiolytic metabolism of the anticancer drug 4′-(9-acridinylamino)methanesulfon-m-anisidide. Biomedical Mass Spectrometry 1981; 8: 485–491
   PubMedGoogle Scholar
• Robbie M. A. Studies on the mechanism of resistance of non-cycling cells to amsacrine and related antitumour drugs. University of Auckland. 1988, PhD thesis
   Google Scholar
• Robbie M. A., Palmer B. D., Denny W. A., Wilson W. R. The fate of N1′-methanesulphonyl-N4′(9-acridinyl)-3′-methoxy-2′,5′-cyclohexadiene-1′,4′-diimine (m-AQD1), the primary oxidative metabolite of amsacrine, in transformed Chinese hamster fibroblasts. Biochemical Pharmacology 1990; 39: 1411–1421
   PubMed Web of Science ®Google Scholar
• Robertson I. G. C., Kestell P., Dormer R. A., Paxton J. W. Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents C1–921 and amsacrine. Drug Metabolism and Drug Interactions 1988; 6: 371–381
   PubMedGoogle Scholar
• Rosi D., Peruzzotti G., Dennis E. W., Berberian D. A., Freele H., Tullar B. F., Archer S. Hycanthone, a new active metabolite of lucanthone. Journal of Medicinal Chemistry 1967; 10: 867–876
   PubMed Web of Science ®Google Scholar
• Shoemaker D. D., Cysyk R. L., Padmanabhan S., Bhat H. B., Malspeis L. Identification of the principal biliary metabolite of 4′-(9-acridinyl-amino)methanesulfon-m-anisidide in rats. Drug Metabolism and Disposition 1982; 10: 35–39
   PubMed Web of Science ®Google Scholar
• Shoemaker D. D., Cysyk R. L., Gormley P. E., De Souza J. J. V., Malspeis L. Metabolism of 4′-(9-acridinylamino)methanesulfon-m-anisidide by rat liver microsomes. Cancer Research 1984; 44: 1939–1945
   PubMed Web of Science ®Google Scholar
• Wilson W. R., Cain B. F., Baguley B. C. Thiolytic cleavage of the antitumour compound 4′-(9-acridinylamino)methanesulphon-m-anisidide (m-AMSA, NSC 156303) in blood. Chemico-Biological Interactions 1977; 18: 163–178
   PubMed Web of Science ®Google Scholar